Publication:
Decidual senescence in recurrent pregnancy loss: forkhead box M1-targeted progesterone treatment

dc.contributor.coauthorKendirci-Katirci, R.
dc.contributor.coauthorKatirci, E.
dc.contributor.coauthorSanhal, C. Y.
dc.contributor.coauthorKirtis, E.
dc.contributor.coauthorSati, L.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorÖzenci, Çiler Çelik
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2026-07-17T08:28:47Z
dc.date.issued2026
dc.description.abstractResearch question What is the role of FOXM1 in the pathogenesis of recurrent pregnancy loss (RPL) characterized by increased decidual senescence, and how do two progesterone analogues (medroxyprogesterone acetate [MPA] and dydrogesterone [DYD]) modulate FOXM1 expression and associated senescence markers in an in-vitro decidualization model? Design Primary decidual cells were isolated from decidual tissue samples collected from women with clinically healthy pregnancies that were terminated voluntarily (control pregnancy group, n = 10) and women with RPL (RPL group, n = 10). Cells were treated with MPA and DYD, and PRL and IGFBP-1 concentrations were analysed by ELISA. FOXO1, FOXM1, phospho-FOXM1 (p-FOXM1), DIO2 and β-GAL expression was examined by immunofluorescence. Co-culture experiments with AC-1M88 trophoblast-like cells assessed spheroid expansion and migration. Results MPA and DYD treatments significantly ameliorated PRL (P = 0.006 and P = 0.015, respectively) and IGFBP-1 (both P
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipThis study was supported by Akdeniz University Scientific Research Projects Coordination Unit (BAP) (project number TDK-2023-6246). Koc University Translational Medicine Research Center (KUTTAM) is funded by the Presidential Presidency of Strategy and Budget.
dc.description.versionPublished Version
dc.identifier.WoSQuartileQ1
dc.identifier.doi10.1016/j.rbmo.2026.105663
dc.identifier.eissn1472-6491
dc.identifier.embargoN/A
dc.identifier.grantnoTDK-2023-6246
dc.identifier.issn1472-6483
dc.identifier.issue2
dc.identifier.pubmed42143847
dc.identifier.scopus2-s2.0-105038987676
dc.identifier.urihttp://doi.org/10.1016/j.rbmo.2026.105663
dc.identifier.urihttps://hdl.handle.net/20.500.14288/33414
dc.identifier.volume53
dc.identifier.wos001779653700001
dc.keywordsDecidual senescence
dc.keywordsDrug therapy
dc.keywordsDydrogesterone
dc.keywordsEndometrium
dc.keywordsForkhead transcription factors
dc.keywordsRecurrent pregnancy loss
dc.languageeng
dc.publisherElsevier
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofReproductive Biomedicine Online
dc.relation.openaccessN/A
dc.rightsN/A
dc.rights.uriN/A
dc.subjectObstetrics
dc.subjectGynecology
dc.subjectReproductive biology
dc.titleDecidual senescence in recurrent pregnancy loss: forkhead box M1-targeted progesterone treatment
dc.typeJournal Article
dspace.entity.typePublication
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files